Inventor
DUDLER THOMAS
US22 patents
⚠️ This page may combine multiple inventors who share the name “DUDLER THOMAS”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
OMEROS CORP
18 patentsUS9644035B2May 9, 2017
Methods for treating conditions associated with MASP-2 dependent complement activation
OMEROS CORP18 citations92
US9475885B2Oct 25, 2016
Compositions for inhibiting MASP-2 dependent complement activation
OMEROS CORP15 citations91
US10059776B2Aug 28, 2018
Methods for treating conditions associated with MASP-2 dependent complement activation
OMEROS CORP2 citations73
US11883493B2Jan 30, 2024
Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders
OMEROS CORP1 citations72
US11027015B2Jun 8, 2021
Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders
OMEROS CORP1 citations72
US10745274B1Aug 18, 2020
Nucleic acids encoding antibodies specifically binding to MASP-3
OMEROS CORP2 citations72
US10639369B2May 5, 2020
Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders
OMEROS CORP2 citations72
US10870708B2Dec 22, 2020
Methods for inhibiting angiogenesis in a subject in need thereof
OMEROS CORP3 citations71
US11896621B2Feb 13, 2024
Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
OMEROS CORP0 citations62
US11884742B2Jan 30, 2024
Methods for treating conditions associated with MASP-2 dependent complement activation
OMEROS CORP0 citations62
US11525011B2Dec 13, 2022
Methods of inhibiting MASP-2-dependent complement activation in a subject suffering from catastrophic antiphospholipid syndrome
OMEROS CORP1 citations62
US11013772B2May 25, 2021
Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
OMEROS CORP0 citations62
US11613589B2Mar 28, 2023
Compositions for inhibiting MASP-2 dependent complement activation
OMEROS CORP0 citations61
US11981748B2May 14, 2024
Methods for inhibiting angiogenesis in a subject in need thereof
OMEROS CORP0 citations60
US12091468B2Sep 17, 2024
Therapeutic antibodies that bind to the serine protease domain of MASP-2 and uses thereof
OMEROS CORP1 citations56
US10202465B2Feb 12, 2019
Methods for treating conditions associated with MASP-2 dependent complement activation
OMEROS CORP0 citations52
US10683367B2Jun 16, 2020
Compositions for inhibiting MASP-2 dependent complement activation
OMEROS CORP0 citations51
US10047165B2Aug 14, 2018
Compositions for inhibiting MASP-2 dependent complement activation
OMEROS CORP0 citations51
SCHWAEBLE HANS-WILHELM
2 patentsUS8652477B2Feb 18, 2014
Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation
SCHWAEBLE HANS-WILHELM61 citations95
US8840893B2Sep 23, 2014
Methods for treating conditions associated with MASP-2 dependent complement activation
SCHWAEBLE HANS-WILHELM36 citations92